drugset / Trial / NCT00951041

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

NCT00951041

Phase 2 Completed 130 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.

Timeline

Start
2009-08-11
Primary completion
2010-08-30
Completion
2010-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK2340269A Vaccine Intramuscular
Subject GSK2340272A Vaccine Intramuscular

Indications